Clover Podiatry has launched the Clover Wound Care Center, a full-service wound care center now serving the Vancouver area (Salmon Creek. Designed to treat chronic and non-healing wounds using advanced, minimally invasive technologies, the new center focuses on lower extremity wounds, including diabetic ulcers, venous wounds, and post-surgical complications. "Wound care is actually one of the most underserved areas in medicine," said Dr. Tek Fish, DPM, founder of Clover Po

Johnson & Johnson announced results from a novel U.S. pilot single-arm trial that evaluated the safety and feasibility of planned Impella 5.5™ support in adult patients undergoing cardiac surgery in the setting of severe left ventricular dysfunction. IMPACT (IMpella Protected cArdiaC surgery Trial) data demonstrated favorable post-operative outcomes and low device-related event rates with planned Impella 5.5 support initiated prior to weaning patients from cardiopulmonary bypass. Th

Redefine Healthcare announced that David Wells-Roth, MD, a board-certified, fellowship-trained neurosurgeon, has become the first provider in the world to perform robotic-assisted spine surgery in an ambulatory surgery center (ASC) using the eCential Robotics platform - a milestone that expands access to advanced surgical technology beyond the hospital setting. The historic procedure took place on March 5, 2026, at the Surgery Center of Hackensack in Hackensack, New Jersey, using th

VolitionRx Limited, a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing. Volition h

CorVista Health has announced a research collaboration with Mayo Clinic to evaluate how next-generation, non-invasive diagnostics may transform the identification and management of pulmonary hypertension (PH) – a complex and frequently underdiagnosed cardiovascular condition that affects an estimated one percent of the global population. Pulmonary hypertension is a progressive and potentially life-threatening condition characterized by elevated pressure in the pulmonary arteri

Pulse Biosciences, Inc, developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at the AF Symposium mee

HOPPR, a company focused on transforming how AI is developed for medical imaging, today introduced its HOPPR™ MC Chest Radiography Narrative Model (MC CXR Narrative Model), a vision language model designed to translate chest X-ray images into descriptive, structured text. The model is designed as a foundational software component that developers can integrate into their own applications to support the development of radiology reporting and image-based workflow solutions. "

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supp

Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed field ablation (PFA), and innovations in cardiac mapping and imaging. At HRS 2026, the company will launch the CARTOSOUND SONATA Module, leveraging artificial intelligence with the CARTO System to automatically transform intracardiac echocardiography (ICE) images into detailed maps, a

QuidelOrtho Corporation a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026. The LEX VELO System is a breakthrough molecular diagnostics platform that is designed to deliver highly sensitive, multiplex RT-PCR testing